Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phynova Ltd.

www.phynova.com

Latest From Phynova Ltd.

Norgine to assess Phynova's botanicals in liver disease

The speciality firm Norgineis to collaborate with Phynova on assessing the latter's product candidates for the treatment of liver disease. Phynova is developing plant-derived products for medicinal use. The collaboration may be extended if it proves to be successful after two or three months, the companies say.

Cancer China

Glenmark sets up clinical R&D centre in Oxford

Glenmark Pharmaceuticalshas set up a clinical R&D centre in Oxford, the UK. to conduct and co-ordinate all clinical R&D development for its small molecules and biologics.

Switzerland

Market Insight - The war on superbugs

Since the development of the first antibiotics, resistant strains of bacteria, in particular Staphylococcus aureus, have increasingly become an obstacle to the successful use of such drugs. When penicillin was first introduced in 1943, resistant S aureus infections were almost unheard of yet, just four years later, a resistant strain was identified. By 1950, around 40% of nosocomial S aureus infections were penicillin-resistant, and this figure rose to around 80% by 1960. Penicillin resistance in S aureus is mediated by β-lactamase. This enzyme is produced by the bacterium and it hydrolyses the β-lactam ring of the penicillin structure, rendering it inactive.

Gastrointestinal Dermatology

Jenken Biosciences Inc.

At present, there are no approved small molecule anti-inflammatory drugs for treating hepatitis C. Indeed, most drug R&D activity for hepatitis centers on new or improved anti-viral therapy rather than complications of the infection, e.g., the chronic inflammation that occurs in 80% of hepatitis cases. Jenken Biosciences hopes to change that. Jenken is repurposing two different, chemically similar, marketed compounds for new indications associated with chronic organ inflammation.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Phynova Ltd.
  • Senior Management
  • Robert Miiller, Managing Dir.
  • Contact Info
  • Phynova Ltd.
    Phone: (44) 1865 784880
    Oxford Science Park
    Magdalen Center
    Oxford, OX4 4GA
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register